Table 2.
Treatment by Genotype, Advanced Stage Patients
| EGFR mutation | KRAS mutation | ALK rearrangement | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Never smoker |
Former/current smoker |
p | Never smoker |
Former/current smoker |
p | Never smoker |
Former/current smoker |
p | |
| Characteristic | N (%) | N (%) | N (%) | N(%) | N (%) | N (%) | |||
| Number of regimens | |||||||||
| Median | 2 | 2 | 1 | 1 | 2 | 2 | |||
| Range | 0–6 | 1–5 | 0–4 | 0–6 | 0–5 | 1–6 | |||
| Treatment with EGFR TKI | |||||||||
| Yes | 60 (88%) | 25 (76%) | 0.57 | 1 (10%) | 8 (7%) | 0.95 | 8 (27%) | 1 (13%) | 0.29 |
| No | 3 (4%) | 3 (9%) | 9 (90%) | 77 (72%) | 22 (73%) | 7 (87%) | |||
| Unknown | 5 (7%) | 5 (15%) | 0 | 22 (21%) | 0 | 0 | |||
| Treatment with crizotinib* | |||||||||
| Yes | 12 (40%) | 3 (40%) | |||||||
| Median duration (months) | 7 | 7 | |||||||
| Mean duration (months) | 7 | 5 | |||||||
| Duration range (months) | 0.4–18.8 | 0.5–8.8 | |||||||
*
Patients were not treated beyond disease progression.